Activating BRAF mutations in eruptive melanocytic naevi

British Journal of Dermatology

Volumn 163, Issue 5, 2010, Pages 1095-1098

  Sekulic, A ^a   Colgan, M B ^b   Davis, M D P ^b   DiCaudo, D J ^a   Pittelkow, M R ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

BRAF; Eruptive naevi; Mutation

Indexed keywords

B RAF KINASE; GENOMIC DNA; MERCAPTOPURINE; MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; ADVERSE OUTCOME; ARTICLE; CASE REPORT; DNA ISOLATION; DNA SEQUENCE; DRUG WITHDRAWAL; ENZYME ACTIVATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; MELANOCYTIC NEVUS; MOLECULAR MECHANICS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIATION MUTAGENESIS; SIGNAL TRANSDUCTION; SUN EXPOSURE; TISSUE SECTION; ULCERATIVE COLITIS;

ADULT; DNA, NEOPLASM; GENOTYPE; HUMANS; MALE; MELANOMA; NEVUS, PIGMENTED; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; SEQUENCE ANALYSIS, DNA; SKIN NEOPLASMS; YOUNG ADULT;

EID: 78249250590     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09989.x     Document Type: Article

References (15)

1. Bovenschen HJ, Tjioe M, Vermaat H, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol 2006; 154: 880 -4.
2. Barker JN, MacDonald DM,. Eruptive dysplastic naevi following renal transplantation. Clin Exp Dermatol 1988; 13: 123 -5.
3. Alaibac M, Piaserico S, Rossi CR, et al. Eruptive melanocytic nevi in patients with renal allografts: report of 10 cases with dermoscopic findings. J Am Acad Dermatol 2003; 49: 1020 -2.
4. Piaserico S, Alaibac M, Fortina AB, et al. Clinical and dermatoscopic fading of post-transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy. J Am Acad Dermatol 2006; 54: 338 -40.
5. Zattra E, Fortina AB, Bordignon M, et al. Immunosuppression and melanocyte proliferation. Melanoma Res 2009; 19: 63 -8.
6. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949 -54.
7. McCubrey JA, Milella M, Tafuri A, et al. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs 2008; 9: 614 -30.
8. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33: 19 -20.
9. Lassacher A, Worda M, Kaddu S, et al. T1799A BRAF mutation is common in PUVA lentigines. J Invest Dermatol 2006; 126: 1915 -17.
10. Thomas NE, Berwick M, Cordeiro-Stone M,. Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation? J Invest Dermatol 2006; 126: 1693 -6.
11. Belloni Fortina A, Piaserico S, Zattra E, et al. Dermoscopic features of eruptive melanocytic naevi in an adult patient receiving immunosuppressive therapy for Crohns disease. Melanoma Res 2005; 15: 223 -4.
12. ODonovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871 -4.
13. Perrett CM, Walker SL, ODonovan P, et al. Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol 2008; 159: 198 -204.
14. Karran P,. Thiopurines, DNA damage, DNA repair and therapy-related cancer. Br Med Bull 2006; 80: 153 -70.
15. Zhang X, Jeffs G, Ren X, et al. Novel DNA lesions generated by the interaction between therapeutic thiopurines and UVA light. DNA Repair (Amst) 2007; 6: 344 -54.